Cardiovascular critical event pathways for the progression of heart failure: A report from the ATLAS study

European Heart Journal

Volumn 22, Issue 17, 2001, Pages 1601-1612

  Cleland, John G F ^a   Thygesen, K ^b   Uretsky, B F ^c   Armstrong, P ^d   Horowitz, J D ^e   Massie, B ^f   Packer, M ^g   Poole Wilson, P A ^h   Ryden L ⁱ  

^a UNIVERSITY OF HULL   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Arrhythymia; Critical events pathways; Heart failure; Ischaemia; Lisinopril; Progression

Indexed keywords

LISINOPRIL;

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; DATA BASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; SUDDEN DEATH; TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; LISINOPRIL; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034875339     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2570     Document Type: Article

References (42)

1. Risk stratification in chronic heart failure
2. How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: Remodelling, resetting, or sudden death?
3. Precipitating factors leading to decompensation of heart failure
4. Preventable causative factors leading to hospital admission with decompensated heart failure
5. Concomitant factors of decompensation in chronic heart failure
6. Is the prognosis of heart failure improving?
7. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure
8. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure
9. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival And Ventricular Enlargement Trial
10. Cardiovascular death and left ventricular remodeling two years after myocardial infarction. Baseline predictors and impact of long-term use of captopril: Information from the survival and ventricular enlargement (SAVE) trial
11. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
12. The epidemiology of heart failure: The Framingham study
13. Dobutamine echocardiography and thallium-201 imaging predict functional improvement after revsacularisation in severe ischaemic left ventricular dysfunction
14. Effect of repetitive episodes of exercise induced myocardial ischaemia on left ventricular function in patients with chronic stable angina: Evidence for cumulative stunning or ischaemic preconditioning?
15. The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS)
16. Incidence and prognosis of unrecognised myocardial infarction: An update on the Framingham Study
17. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularisation
18. Myocardial cell death and apoptosis in hibernating myocardium
19. Systematic review of the management of atrial fibrillation in patients with heart failure
20. Anticoagulant and antiplatelet therapy in heart failure
21. Ventricular dysfunction and the risk of stroke after myocardial infarction
22. Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study
23. Comparative effects of low doses and high doses of the angiotensin converting-enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
24. Ischemia as a 'trigger' for sudden death in patients with cardiomyopathy and heart failure secondary to coronary artery disease: Results from the ATLAS trial (Abstr)
25. Sudden death in heart failure: Vascular or electrical?
26. Effect of antithrombotic therapy on risk of sudden coronary death in patients with congestive heart failure
27. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
28. Warfarin anticoagulation and survival: A cohort analysis from the studies of left ventricular dysfunction
29. Meeting report - The LIDO, HOPE, MOXCON and WASH studies
30. The role of subendocardial ischemia in perpetuating myocardial failure in patients with non-ischemic congestive cardiomyopathy
31. Trandolapril reduces the incidence of atrial fibrillation following acute myocardial infarction
32. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation
33. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
34. Successes and failures of current treatment of heart failure
35. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
36. Mode of death in chronic heart failure - A request and proposition for more accurate classification
37. Myocardial infarction and coronary deaths in the World Health Organisation MONICA project
38. A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
39. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
40. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
41. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients
42. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions